Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lenalidomide plus escalating-dose chemotherapy in high-risk myelodysplastic syndrome or acute myeloid leukemia with del(5q31)
2008-006032-36Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Response. Started Nov 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2008-006032-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006032-36.